Bevacizumab + Anetumab Ravtansine/Paclitaxel for Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies the side effects of bevacizumab and anetumab ravtansine or paclitaxel in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that does not respond to treatment (refractory). Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Anetumab ravtansine is a drug that targets a protein in the body called mesothelin, which can be found in some ovarian, pancreatic and other tumors. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving bevacizumab and anetumab ravtansine or paclitaxel may work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop your current medications, but you cannot take strong inhibitors or inducers of CYP3A4 within 2 weeks before and during the trial. It's best to discuss your current medications with the study team to ensure they don't interfere with the trial.
Is the combination of Bevacizumab and Paclitaxel safe for treating ovarian cancer?
The combination of Bevacizumab (Avastin) and Paclitaxel has been studied for ovarian cancer, showing some safety concerns. In heavily pre-treated patients, serious side effects like gastrointestinal perforations (holes in the stomach or intestines) and fistulas (abnormal connections between organs) occurred in a small percentage of patients. However, no treatment-related deaths were reported.12345
How is the drug combination of Bevacizumab, Anetumab Ravtansine, and Paclitaxel unique for treating ovarian cancer?
This drug combination is unique because it includes Anetumab Ravtansine, which is not commonly used in standard ovarian cancer treatments. Bevacizumab targets blood vessel growth in tumors, while Paclitaxel disrupts cancer cell division, and the addition of Anetumab Ravtansine may offer a novel approach by targeting specific proteins on cancer cells.36789
What data supports the effectiveness of the drug combination Bevacizumab + Anetumab Ravtansine/Paclitaxel for ovarian cancer?
Research shows that combining bevacizumab with other drugs like paclitaxel can be effective in treating ovarian cancer, with studies indicating improved survival rates and response in patients. Additionally, similar drug combinations have shown significant activity in recurrent ovarian cancer, suggesting potential benefits for this treatment approach.710111213
Who Is on the Research Team?
Stephanie Lheureux
Principal Investigator
University Health Network Princess Margaret Cancer Center LAO
Are You a Good Fit for This Trial?
This trial is for patients with certain types of ovarian, fallopian tube, or primary peritoneal cancer that have not responded to platinum-based chemotherapy. Participants must have measurable disease progression and be in good enough health to perform daily activities (ECOG <=2). They should not have had recent major surgeries or other treatments and must agree to use contraception if applicable.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive either anetumab ravtansine and bevacizumab or paclitaxel and bevacizumab in 28-day cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Anetumab Ravtansine
- Bevacizumab
- Paclitaxel
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor